



The ability to ward off pathogens is essential for the survival of a species. Programmed 
cell death plays an important role in defending against intracellular pathogens. There are three 
main forms of programmed cell death, each initiated by distinct pathways: apoptosis, 
necroptosis, and pyroptosis. Previous work by the Miao lab has shown that caspase-1 driven 
pyroptosis can efficiently clear intracellular bacteria. This was demonstrated by using an 
engineered strain of Salmonella that selectively triggers pyroptosis in the presence of 
tetracycline. I took two approaches to determine how apoptosis would compare to pyroptosis in 
the ability to clear a bacterial infection. First, I took advantage of the fact that caspase-1 can also 
activate the caspase-9 dependent apoptotic pathway when pyroptosis is blocked. Therefore, I 
examined our caspase-1 engineered Salmonella strain in knockout mice, which should convert 
the induction of pyroptosis to apoptosis. Second, I engineered a new strain of Salmonella to 
directly induce apoptosis by delivering an apoptotic protein which also triggers caspase-9 
dependent apoptosis. Currently, my results suggest that unlike pyroptosis, apoptosis is unable to 
clear Salmonella infections in vivo. Future work will determine if apoptosis is unable to clear 
Salmonella due to a basic inability of apoptosis to clear pathogens, or if Salmonella has evolved 
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There are two main categories of cell death: programmed and accidental. Programmed 
cell death included apoptosis, pyroptosis, and necroptosis. Apoptosis is a non-lytic, non-
inflammatory type of cell death that is most commonly used as part of tissue development and 
the cell cycle, although it also plays a role in immune defense against both bacteria and viruses. 
Pyroptosis and necroptosis are both lytic, pro-inflammatory forms of cell death whose main roles 
are as an immune defense against bacteria and viruses, respectively. Necrosis is an accidental 
form of cell death, which results from physical trauma, is lytic, and causes a non-infectious 
inflammatory response. Pyroptosis is initiated by caspases-1 or caspase-11, which are activated 
by inflammasomes, and is characterized by the cleavage of gasdermin-D, which forms a 26-mer 
pore on the cell membrane1.  Pyroptotic inflammasomes are attuned to signs of both extracellular 
and intracellular bacterial infections, including physical bacterial subunits and virulence factors, 
lipopolysaccharide (LPS), bacterial DNA and dsRNA, toxins, and potassium efflux2.  
Salmonella enterica serovar Typhimurium is a common model used to study intracellular 
infection, and is ideal for studying cell death as it evades both pyroptosis and apoptosis in vivo. 
There are 1.2 million cases of S. Typhimurium in the US each year, and it remains an important 
gut pathogen to study. There are two main stages for S. Typhimurium infections: the 
extracellular stage, which occurs in the gut lumen, and the intracellular stage, which occurs in 
macrophages in the spleen and in epithelial cells.  During the extracellular stage, S. 
Typhimurium are located in the cytosol, are producing flagellin to travel, and are utilizing a SPI1 
type III secretion system (T3SS), a molecular syringe the bacteria use to send effector proteins 
into the cytosol, which causes vacuolar modifications. The extracellular stage is when S. 
Typhimurium are most likely to be detected and cleared by the host cell. During the intracellular 
stage, S. Typhimurium are located in vacuoles of the host cell, have suppressed flagellin 
production, and switched to a SPI2 T3SS. In this stage, S. Typhimurium are able to evade 
detection by the host cell, and at this point wild type (Bl/6) mice are unable to clear wild type S. 
Typhimurium and succumb to the infection. There are two main reasons that S. Typhimurium are 
detected during the extracellular stage but not the intracellular 
stage: the switch from a SPI1 to SPI2 T3SS and the suppression 
of flagellin production. The proteins that make up the molecular 
syringe for the SPI2 T3SS are not detected by the cell the same 
way the SPI1 T3SS are. A major factor for S. Typhimurium 
evasion is the suppression of flagellin production. When flagella 
are being produced, flagellin monomers are secreted through the 
hollow core of the flagellum polymer to allow it to lengthen and 
form the full flagellum appendage. However, these flagellin 
monomers can also be accidently translocated through the 
virulence-associated SPI1 and SPI2 T3SS instead, resulting in 
detection by the host (Figure 1). Suppressing flagellin expression 
allows S. Typhimurium to successfully evade detection by the 
host cell (Figure 2).  
Figure 1 
Type Three Secretion signal (left) 
and flagellum apparatus (right), and 
a flagellin monomer (blue) 
translocated through the T3SS into 
the cell instead of through the 
flagellum appendage. 
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The Miao lab previously 
engineered a strain of S. Typhimurium 
that is forced to induce expression of 
flagellin in the presence of the drug 
doxycycline (FliCIND)3 (Figure 3). This 
flagellin passes through the SPI2 type 
III secretion system, where it is then 
detected by inflammasomes, triggering 
pyroptosis4 (Figure 2). Dr. Miao 
showed that the FliCIND bacteria, 
which initiated pyroptosis, were 
robustly cleared when compared to 
wild-type S. Typhimurium using a 
competitive index model (see 
Methods). Moreover, this clearance 
only occurred in mice possessing all 
the genes involved in the 
inflammasome pathway, showing that 
these engineered bacteria were normal 
in the absence of the inflammasome 
sensor3. While the apoptotic pathway 
is well characterized, it is unknown 
how apoptosis affects S. Typhimurium. 
Apoptosis has two main roles: 
developmental and immunological. 
Triggers for developmental apoptosis 
are tissue formation, and self-
recognition of potentially harmful 
cells, and is mainly induced by DNA 
damage and ER stress. Immunological 
apoptosis is characterized by initiator 
caspases-8 and -9, and effector 
caspases-3, -6,and -7. It is triggered by 
LPS, dsRNA, TNF, and granzymes. 
Both viruses and bacteria have 
apoptosis inhibitors, and because of 
this it has been inferred that apoptosis 
must be detrimental to the virulence 
cycle for both pathogens. Further 
illustrating the immunologic impact of 
apoptosis, it has been shown that 
asthma, atherosclerosis, and lupus all 
have connections with improper 
clearance of apoptotic bodies, and the 
non-inflammatory associations with 








S. Typhimurium in vacuoles of macrophages in the spleen. 
Left: WT S. Typhimurium evades detection and lives. Middle: 
FliCIND is forced to express flagellin, is detected by the cell, 
triggers the pyroptotic pathway, and FliCIND are killed. Right: 
ApopIND triggers the apoptotic pathway. It is unknown how 
apoptosis will affect S. Typhimurium. Caspase-1 can also 
trigger the apoptotic pathway 
Figure 3 
FliCIND: Tetracycline-inducible flagellin plasmid. Contains the 
tetracycline inducible system followed by a flagellin monomer 
and chaperone.  
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therapies to promote transplant tolerance5.  Since the primary role of pyroptosis in clearing 
infection is to kill the infected cell, I hypothesized that apoptosis should also clear intracellular 




A single mouse is infected with a 1:1 ratio of a mutant (AmpR) and wild type (KanR) S. 
Typhimurium for a total CFU of either 105 or 103.  After 48h (105 CFU) or 24h (103CFU), the 
mice are treated with 0.8g/mouse of doxycycline. 24 hours after treatment, the spleen is 
harvested, homogenized, and seven tenfold dilutions are made (for a total of 8 dilutions from 1-
10-7). These dilutions are plated in triplicate on both ampicillin plates and kanamycin plates. The 
plates are incubated at 37C overnight, and the spots counted the next day to determine relative 
counts of each strain of bacteria in the spleen at the time of harvest. These results are graphed on 
a log(mutant/WT) scale, where -1 on the y axis corresponds to tenfold more wild type bacteria 
than mutant strain, 0 corresponds to equal amounts of mutant and wild type, and +1 corresponds 
to tenfold more mutant strain than wild type S. Typhimurium. Due to a frequent occurrence of 
moribund or dead mice at the time of harvest, experimental parameters were changed from 48h 
initial infection period at 105 CFU to 24h infection period at 103 CFU as of 10/11/18. Results 
from these experiments were not affected by the change in infection period and CFU dose, but 
mouse health at the end of the study greatly improved.   
 
Doxycycline 
We use a 0.8mg/mouse dosage for doxycycline. Starting 10/11/18, doxycycline was made in 
large batches that were then aliquoted and frozen for future use. Doxycycline is made using a 
4mg/ml concentration in PBS, pH-ed to 7.4, then filter sterilized with a 0.22µm filter.  
 
PCR 
Cloning PCRs occurred in 50µl reactions, while diagnostic PCRs were limited to 20µl reactions. 
A Phusion-based protocol was followed for closing while Taq was used for diagnostic PCRs. 




Most ligations occurred using a 3:1 ratio, although up to a 10:1 ratio was used. Calculations for 
the ligation were done using Insilico’s ligation calculator. Ligations were allowed to sit overnight 
at room temperature prior to transforming.  
 
Digestion 
Digestions occurred in 50µl reactions using enzymes compatible with cutsmart buffer. SAP 
phosphatase was added to vectors to prevent self-ligation. A thermocycler was used to incubate 
the sample at 37C for 4 hours followed by 15 minutes at 72C.  
 
In vitro infections 
HeLa Cells: 
Cells seeded in a 24 well plate at 2x105 cells per well overnight were infected with an MOI of 20 
for 1 hour, then treated with 100µg of gentamycin, followed an hour later by 10µg of 
doxycycline. Cells imaged using an EVOS microscope 2-4 hours post-doxycycline.  
Bone marrow macrophage fluorescence: 
Cells seeded in 1.75 cells/well overnight, then half the wells were infected with MOI of 25 for 
one hour, and half left uninfected. All wells were treated with 7.5µg gentamycin 1 hour post-
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infection, followed 3 hours later by 30µg of doxycycline. At the time doxycycline was added, 
half the uninfected cells were treated with 50ng of TNF and 3ng of CHX as a positive apoptotic 
control. Wells were imaged every hour for up to 5 hours post doxycycline (one set of images 
taken 0h post doxycycline for a total of 6 sets of images). 5 minutes prior to imaging, 5µl of 
Annexin-V red and 30µM of DAPI were added to cells to stain apoptotic membranes and nuclei 
of cells with disrupted membranes.  
 
ELISA 
BMM were seeded with 5x104 cells/well and infected with decreasing MOIs of 50, 25, 12.5, and 
6.25 for 1 hour prior to 7.5µg gentamycin. Total infection time of 4 hours before supernatants 
were saved for ELISA. An Il-1B ELISA was run according to the protocol provided by R&D 
systems.   
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Results 
 To first test the effect of apoptosis on S. 
Typhimurium infection, I took advantage of the backup 
pathway between pyroptosis and apoptosis when pyroptosis 
is blocked (Figure 2). Since FliCIND-containing S. 
Typhimurium  (FliCIND) has been shown to be an effective 
inducer of pyroptosis, I chose to infect KO mice with a 
constitutive version of FliCIND, FliCON, to induce apoptosis 
instead of pyroptosis without the variable of adding 
doxycycline (Figure 4). Bl/6 mice showed clearance of 
FliCON through pyroptosis as expected. Casp1/11-/- showed 
no clearance, also as expected since without caspase-1, 
neither the pyroptotic nor apoptotic pathways can be 
induced. However, the KO group also showed no clearance 
of FliCON, suggesting that apoptosis is unable to clear S. 
Typhimurium infections.  
 To further confirm this, I created an apoptosis-
inducible plasmid based off of FliCIND, called ApopIND 
(Figure 5). This plasmid incorporates three regions of 
interest. The first is a tetracycline promoter, so the 
downstream regions of the plasmid are only expressed in 
the presence of doxycycline. Next is a secretion signal, 
which is translocated by the SPI2 type III secretion system. 
This secretion signal was fused to the inducible protein. 
This 20 amino-acid length domain is all that is required to 
initiate a pathway that will ultimately activate the 
apoptotic-effector caspases, leading to apoptosis. I first 
confirmed that ApopIND did induce apoptosis in the 
presence of doxycycline in HeLa cells, then again in bone 
marrow macrophages using fluorescence to localize GFP-
containing ApopIND to cells that morphologically looked apoptotic, and were also Annexin-V and 
DAPI positive (Figure 6). Annexin-V stains to apoptotic membranes and DAPI is a nuclear stain. 
Both sets of imaging confirmed that ApopIND resulted in higher than baseline amounts of 
apoptosis occurring in cells within 2 hours.  
Figure 4 
 
Competitive index of FliCON in Bl/6, 
Caspase 1/11 -/-, and KO. 
 
Figure 5 
Based on FliCIND, ApopIND has same 
tetracycline inducible portion followed by a 









 With ApopIND confirmed to work in vitro, I then ran a competitive index experiment 
comparing ApopIND in Bl/6 mice to FliCIND in KO (Figure 7). I found that ApopIND showed the 
same lack of clearance as FliCIND in KO. A rotating graduate student also conducted a time 
Above: (A) uninfected HeLa cell, (B) HeLa cell 
infected with wild type Salmonella, (C-D) HeLa cells 
infected with ApopIND–containing Salmonella after 
tetracycline has been administered. (C) Shows very 
early stages of apoptosis with the cell pulling in and 
some blebs beginning to form, while (D) shows a 
slightly later stage of apoptosis, with several classic 
apoptotic blebs around the edges of the cell. 
Right: (A) uninfected BMMs, (B) BMMs infected with 
wild type GFP-containing Salmonella, (C) ApopIND- 
and GFP-containing Salmonella, and (D) BMMs 
treated with TNF+CHX as a positive control for 
apoptosis. Arrows are pointing to representative cells 
identified as apoptosis-positive in each sample. BMMs 
are stained with DAPI (blue, nuclear stain) and 
Annexin-V (red, apoptotic membranes).  
 
Figure 6 
(A) Competitive index verifying that ApopIND in Bl/6 mice has the same lack of clearance as FliCIND in KO.  FliCIND 
Salmonella in Bl/6 are cleared through pyroptosis, while FliCIND Salmonella in KO  and ApopIND Salmonella in Bl/6 
and KO mice all show no clearance.  (B) Competitive index where Bl/6 mice were infected with one of three mutant 
strains of Salmonella: a “vector-only” control (the vector and tetracycline inducible portion of ApopIND without the 
secretion signal or inducible protein), ApopIND, or FliCIND. (C) Competitive index time course of ApopIND, testing 
different lengths of time post-doxycycline prior to harvesting the spleen.  
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course to test different lengths of time post-doxycycline treatment prior to harvesting the spleen 
and found that maximum effectiveness was reached at approximately 24 hours, which agrees 
with previous findings of Miao et al in FliCIND  3 (Figure 7C). Overall, it does appear that 
apoptosis from FliCIND in KO and ApopIND in Bl/6 do lead to a weak increase in total bacterial 
burden. However, a competitive index looking at ApopIND versus a vector only control (ApopIND 
minus secretion signal and the inducible protein) did not reliably show a statistically significant 
increase in burden from the vector control to ApopIND (Figure 7B). As such, the only conclusion I 
will make at this time is that apoptosis seems unable to clear S. Typhimurium infections from the 
spleen. Before fully accepting this conclusion, future work will need to verify that our plasmid is 
actually inducing apoptosis in vivo.  
 I came up with two main hypotheses for why 
apoptosis may be unable to clear S. Typhimurium 
infections. The first is that apoptotic bodies function as 
taxis. Macrophages are the primary cell type infected 
by S. Typhimurium, but macrophages are also the 
primary phagocyte for apoptotic bodies. In addition, 
macrophages are not as bactericidal as neutrophils, 
which Miao et al showed to be the cause of bacterial 
clearance after pyroptosis occurs3. This led me to 
hypothesize that apoptosis could be allowing S. 
Typhimurium to spread to a new host cell. There is 
precedent for this hypothesis with the “Trojan horse” 
strategy of Chlamydia pneumoniae, which is able to 
nudge the macrophage towards a non-inflammatory 
response once it has been phagocytosed, and continue 
to replicate within, using the macrophage as a new host 
cell. In the study by Miao et al, they found that FliCON 
bacteria in an Ncf1-/- with defective reactive oxygen 
species and deficient neutrophils are no longer cleared 
and are also able to replicate and survive inside the 
defective neutrophils. I chose to compare FliCIND to 
ApopIND in Ncf1-/- to see if the apoptotic phenotype 
matches one known to involve S. Typhimurium 
replicating inside phagocytes (Figure 8). These two 
phenotypes did indeed match, leading credence to the 
hypothesis that macrophages during apoptosis may be 
acting as a path to new host cells for S. Typhimurium.  
 My second hypothesis was that S. Typhimurium 
have a mechanism that allows them to leave a dying cell. 
Specifically, I hypothesized that there may be a SPI2 
effector that could lyse membranes during apoptosis, 
which would allow S. Typhimurium to escape and start 
the infection cycle over again. I chose to focus on a SPI2 
effector whose enzymatic activity is dependent on RhoA. 
RhoA activates ROCK, a protein that drives blebbing 
during apoptosis, although it is unclear is RhoA is needed 
Figure 8 
 
Competitive index with FliCIND and ApopIND in 
Ncf1-/-. 
Figure 9 
Competitive index comparing FliCON to 
ΔsseJ FliCON in KO and ApopIND to ΔsseJ 
ApopIND in Bl/6. ΔsseJ strains compared to 
ΔsseJ ‘wild type’ to adjust for differences in 
virulence. 
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during the apoptotic activation of ROCK. If it is, this effector may also be activated during 
apoptosis. Furthermore, in certain mutants, this effector is thought to lyse the membrane of the 
vacuole, as a double mutant cannot lyse the membrane4. I then compared my normal ApopIND to 
a Δeffector ApopIND in Bl/6 mice, and FliCIND to a Δeffector FliCON to see if Δeffector S. 
Typhimurium would lose the ability to avoid clearance via apoptosis (Figure 9). While the 
burdens for the Δeffector strains were decreased compared to the normal inducible strain, it did 
not result in clearance of S. Typhimurium, suggesting that either this effector does not play a role 
in allowing S. Typhimurium to escape a dying cell, or that there is likely redundancy and this 
effector is not the only effector protein at play. I already have other targets in mind as a possible 
lysis protein that S. Typhimurium could be using to escape apoptotic bodies12. 
 Due to the weak but consistent increase in burden seen during apoptosis in both the 
FliCON/IND in the KO model and ApopIND in Bl/6 model, I 
chose to take a second look at the ApopIND plasmid 
construct to increase efficiency of my system and attempt 
to resolve if that weak increase is true phenotype or 
random occurrence (Figure 10). Tetracycline-inducible 
systems like the one implemented in the FliCIND and 
ApopIND plasmids were first published for use in 
mammalian cells in 1992, and are based on a native 
system in E. coli. This inducible system has been 
thoroughly studied to improve the inducible response 
since then6,7. FliCIND, and therefore ApopIND were both 
created using the original native tetracycline-inducible 
system, but there are engineered tetracycline-inducible 
promoters which are much shorter and more strongly 
activated by tetracycline than the native system6,7. 
Specifically, I have chosen PLtet-O1 as the new promoter, 
which is an 86bp sequence that has been shown to have 
strong activation in the presence of doxycycline and 
artificial doxycycline derivatives that can activate a 
tetracycline-inducible system without the antibacterial 
properties6,7,8. Second, while Dr. Miao previously showed 
that our chosen secretion signal is strongly translocated 
by the SPI2 T3SS, it was later shown that it is nuclear 
localized4. For our system to be efficient, the inducible 
protein needs to be delivered directly to the cytosol, not 
the nucleus. I am now looking at multiple possible 
secretion signals previously shown to be highly 
translocated during the SPI2 phase. Finally, I am 
examining the “inducible cargo” portion of the plasmid. While the inducible protein was an easy 
target for this system to be able to deliver, there are other similar domain proteins within the 
apoptosis effector family that could also be promising for mitochondrial activation9,10,11. For 
FliCIND, the current FliC monomer used contains four domains, but only one of those domains, 
D0, is detected by NAIP5/6 of NLRC4 for pyroptosis activation. I am therefore planning on 
creating a new version of FliCIND, called PyroIND, which will have the new tetracycline promoter 
and only the D0 domain of FliC as the insert (Figure 10). 
Figure 10 
Above: New inducible cell death plasmid 
structure with new tetracycline-inducible 
promoter, SseJ secretion signal, and insert. 
Below: PyroIND with new tetracycline 
promoter and simplified FliC domains. 
insert	
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 I was able to run an initial test to determine whether a cytosolic signal would be a 
promising new secretion signal. I used a version of FliCON that utilized the new secretion signal, 
and compared it in vitro to the existing FliCON to compare the total amount of pyroptosis that 
occurred in infected cells. I found that the FliCON + SS group had no difference from the wild 
type S. Typhimurium control, meaning it did not secrete a functional FliC monomer. It is 
possible this is due to binding malfunctions with both a secretion signal and the FliS chaperone 
attempting to bind to FliC to guide it through the T3SS, but further experiments are required to 
see if this is the case.  
 
Abele	15	
Discussion and Conclusion 
 My data suggest that apoptosis does not result in clearance of S. Typhimurium. I used 
two model systems that cause apoptosis through two different pathways: the caspase-1 dependent 
backup pathway and the mitochondrial pathway. Assuming that the conclusion that apoptosis is 
not useful against S. Typhimurium holds us after further validation, we then have to ask is 
apoptosis ineffective at clearing intracellular bacterial infections from the spleen, or has S. 
Typhimurium evolved to escape the consequences of apoptosis? If the answer lies in some fault 
on behalf of apoptosis, this may provide useful information on why pyroptosis would have 
evolved, when the inflammation and potential cytokine storm can both cause severe tissue 
damage and long-term requires higher energy expenditure for the host. The negative 
consequences of sustained inflammation to the host means most medicines are focused on 
reducing the amount of inflammation, not increasing it. If apoptosis, the non-inflammatory 
pathway, is determined to be unable to clear a bacterial infection, this would provide a case for 
when inflammation is not only a benefit, but is critical for clearance. This could be tested using 
the wild type S. Typhimurium that are able to evade detection, and then stimulating the mouse 
immune system with a mild local irritant to cause inflammation near the spleen, and determining 
if bacterial burdens were decreased by non-specific inflammation. If the answer lies in the ability 
of S. Typhimurium to escape the consequences of apoptosis, we then have to ask why can it not 
use that system to escape the consequences of pyroptosis? Is S. Typhimurium able to escape 
apoptotic bodies by lysing the membrane, or does it behave like C. pneumoniae and can push the 
macrophages phagocytizing apoptotic bodies into a non-inflammatory response, thereby using 
apoptosis as a method to gain new host cells? 
Finally, I will be moving this work into another model organism, Listeria 
monocytogenes. While S. Typhimurium are gram negative, vacuolar organisms, L. 
monocytogenes are cytosolic and gram positive, although both infect macrophages in the spleen. 
Although it is unknown how apoptosis will affect L. monocytogenes in the spleen, previous 
literature has shown L. monocytogenes clearance from the liver via apoptosis due to the adaptive 
immune system. Creating ApopIND L. monocytogenes would allow me to test burdens in two 
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